Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease

Critical Care Medicine

Volumn 37, Issue 3, 2009, Pages 980-986

  Yin, Ning ^a,b   Kaestle, Stephanie ^a   Yin, Jun ^a,b   Hentschel, Thomas ^b,c   Pries, Axel R ^a   Kuppe, Hermann ^b   Kuebler, Wolfgang M ^a,b,d,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Congestive heart failure; Iloprost; Inhaled vasodilators; Nitric oxide; Pulmonary hypertension

Indexed keywords

CYCLIC AMP; CYCLIC GMP; ILOPROST; NITRIC OXIDE; NITROPRUSSIDE SODIUM; SODIUM CHLORIDE; VASODILATOR AGENT;

AEROSOL; AIRWAY PRESSURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL VENOUS PRESSURE; CHRONIC DRUG ADMINISTRATION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DRY WEIGHT; HEART LEFT ATRIUM PRESSURE; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG WEIGHT; MALE; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REPEATED DRUG DOSE; SHAM PROCEDURE; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; SYSTEMIC VASCULAR RESISTANCE; TIDAL VOLUME; ANIMAL; COMPARATIVE STUDY; HEART FAILURE; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; HEART FAILURE; HYPERTENSION, PULMONARY; ILOPROST; MALE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 62849128660     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181962ce6     Document Type: Article

References (31)

1. Ghio S, Gavazzi A, Campana C, et al: Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183-188
2. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436
3. Haraldsson A, Kieler-Jensen N, Ricksten S: The additive pulmonary vasodilator effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93: 1439-1445
4. Sablotzki A, Czeslick E, Schubert S, et al: Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can J Anaesth 2002; 49:1076-1080
5. Sablotzki A, Hentschel T, Gruenig E, et al: Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 2002; 22:746-752
6. Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure: The role of the endothelium in pathophysiology and management. Circulation 2000; 102:1718-1723
7. Delgado JF, Conde E, Sanchez V, et al: Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005; 7:1011-1016
8. Di Salvo TG, Mathier M, Semigran MJ, et al: Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995; 25:1143-1153
9. Polak JF, Holman BL, Wynne J, et al: Right ventricular ejection fraction: An indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol 1983; 2:217-224
10. Califf RM, Adams KF, McKenna WJ, et al: A randomized controlled trial of epoproste-nol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134:44-54
11. Packer M, Carver JR, Rodeheffer RJ, et al: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468-1475
12. Packer M, Lee WH, Medina N, et al: Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987; 10:1303-1311
13. Olschewski H, Olschewski A, Rose F, et al: Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001; 138:287-297
14. Natori S, Hasebe N, Jin YT, et al: Inhaled nitric oxide modifies left ventricular diastolic stress in the presence of vasoactive agents in heart failure. Am J Respir Crit Care Med 2003; 167:895-901
15. Hentschel T, Yin N, Riad A, et al: Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology 2007; 106:124-131
16. Peterson BT, Brooks JA, Zack AG: Use of microwave oven for determination of postmortem water volume of lungs. J Appl Physiol 1982; 52:1661-1663
17. Hayward CS, Kelly RP, Macdonald PS: Inhaled nitric oxide in cardiology practice. Cardiovasc Res 1999; 43:628-638
18. Van Dyke RE, Nikander K: Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb adaptive aerosol delivery systems: An in vitro study. Respir Care 2007; 52:184 -190
19. Budhiraja R, Tuder RM, Hassoun PM: Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109:159-165
20. Huang W, Kingsbury MP, Turner MA, et al: Capillary filtration is reduced in lungs adapted to chronic heart failure: Morphological and haemodynamic correlates. Cardiovasc Res 2001; 49:207-217
21. van Veldhuisen DJ, Poole-Wilson PA: The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. Int J Cardiol 2001; 80:19-27
22. Karatasakis GT, Karagounis LA, Kalyvas PA, et al: Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure. Am J Cardiol 1998; 82:329-334
23. Abramson SV, Burke JF, Kelly JJ Jr, et al: Pulmonary hypertension predicts mortality and morbidity in patients with dilated car-diomyopathy. Ann Intern Med 1992; 116: 888-895
24. Ghofrani HA, Wiedemann R, Rose F, et al: Lung cGMP release subsequent to NO inhalation in pulmonary. Eur Respir J 2002; 19: 664-671
25. Beghetti M, Sparling C, Cox PN, et al: Inhaled NO inhibits platelet aggregation and elevates plasma but not intraplatelet cGMP in healthy human volunteers. Am J Physiol Heart Circ Physiol 2005; 285:H637-H642
26. Barnes PJ, Liu SF: Regulation of pulmonary vascular tone. Pharmacol Rev 1995; 47: 87-131
27. Hoeper MM, Olschewski H, Ghofrani HA, et al: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35:176-182
28. Sayner SL, Alexeyev M, Dessauer CW, et al: Soluble adenylyl cyclase reveals the significance of cAMP compartmentation on pulmonary microvascular endothelial cell barrier. Circ Res 2006; 98:675-681
29. Matthay MA, Robriquet L, Fang X: Alveolar epithelium: Role in lung fluid balance and acute lung injury. Proc Am Thorac Soc 2005; 2:206-213
30. Sablotzki A, Starzmann W, Scheubel R, et al: Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth 2005; 52: 1076-1082
31. Coleman TJ: Cardiac output by dye dilution in the conscious rat. J Appl Physiol 1974; 37:452-455